23.05.2012 - British respiratory medicines company Prosonix Ltd. has extended its Series B financing round to £17.1m.
Oxford – The lion’s share of the new capital comes from new investor Gimv, a leading European technology investor, who contributed £5.7m. The rest was contributed by the syndicate of investors that participated in the first closing of the round in June 2011. The syndicate includes Ventech, Gilde Healthcare Partners, Entrepreneurs Fund, Quest for Growth and Solon Ventures.
The Oxford-based Prosonix announced it will use the proceeds of the financing to push forward its product pipeline of inhalable mono- and combination therapies. “These new funds will enable Prosonix to accelerate its activities aimed at attaining key performance and clinical data for our pipeline of excipient-free, drug-only respiratory medicines”, said David Hipkiss, Prosonix' CEO. His company works on development programs for an inhaled corticosteroid for asthma and a long-acting muscarinic antagonist for chronic obstructive pulmonary disorder. Its unique Multi-component Particle (MCP™) platform enables Prosonix to combine two or more drug molecules consistently in a pre-determined ratio in each and every particle in the formulation.
Karl Nägler, Venture Capital Partner at new investor Gimv, will join the Prosonix board as a Non-executive Director. „We are confident that Prosonix can become a significant player in the area of respiratory medicines“ said Nägler, stressing that Prosonix is at an important point in its development.
12.05.2015 US pharma is coming to European biotech to fill their pipeline. Pfizer is paying €77.5m for an option on Dutch AM-Pharma, while Juno Therapeutics acquired German biotech Stage Cell Therapeutics for around €72m.
26.05.2015 The Finnish Medicines Agency Fimea has joined the Dutch MEB in its stance on the interchangeability of biosimilars. The Fimea now sees physician-driven switching of biologics as unproblematic.
20.05.2015 The Scottish Government has announced it will double the amount of funds for rare diseases. The New Medicines Fund that was created last year for this purpose will be increased to £80m (€112m).
30.04.2015 The European Parliament has given the go-ahead on a new law limiting the use of harmful crop-based biofuel in the transport sector. The decision marks a breakthrough in the EU’s approach to biofuels.
SuperScript® III Reverse Transcriptase (RT) is a proprietary mutant of SuperScript® II RT that is active at 50°C and has a half-life of 220 minutes, providing increased specificity with gene-specific primers (GSPs) and the highest cDNA yield of all RTs. more